Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies

A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies

OBJECTIVES The paediatric idiopathic inflammatory myopathies (IIMs) are a group of rare chronic inflammatory disorders of childhood, affecting muscle, skin and other organs. There is a severe lack of evidence base for current treatment protocols in juvenile myositis. The rarity of these conditions means that multicentre collaboration is vital to facilitate studies of pathogenesis, treatment and...

Approach to Diagnosis and Management of an Idiopathic Inflammatory Myopathy

Idiopathic inflammatory myopathies are a group of autoimmune diseases characterized by proximal muscle weakness and inflammation of skeletal muscle. Specific forms of idiopathic inflammatory myopathy include polymyositis, dermatomyositis, and inclusion body myositis. Inflammatory myopathies have a bimodal distribution, occurring in patients between 10 and 15 years and 45 and 60 years of age, ex...

The idiopathic inflammatory myopathies and their treatment.

Current pharmacological treatment of idiopathic inflammatory myopathies.

The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype. There are few randomised, double blind placebo controlled ...

Comparison of data from the juvenile dermatomyositis national (UK & Ireland) cohort biomarker study and repository for idiopathic inflammatory myopathies with a survey of current practice throughout the UK and Ireland

Results Fifteen of 16 Paediatric Rheumatology centres responded to the survey. For initial treatment of patients with mild disease 13/15 centres report using a combination of steroids and methotrexate and 8/15 would also use IV methylprednisolone. For moderately severe disease all centres use steroids and methotrexate and 11/15 also use IV methylprednisolone. With severe weakness, ulceration or...